Clinical trials: Liver Inflammation
Hepatitis B
Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV.
To investigate the durability of HBeAg seroconversion in patients with chronic hepatitis B virus infection (HBV) who have seroconverted while participating in a previous Gilead-sponsored study of adefovir dipivoxil.
- Trial name
- NCT00158717
- Testing
- Hepsera
- Volunteers
- 107 people
- Sponsor
- Gilead Sciences
Hepatitis B, Healthy
First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection
This is a Phase 1, first in human study of ChAdOx1-HBV. The study will be conducted in 40 healthy participants and 12 participants with CHB and virally suppressed with oral antiviral medication.
- Trial name
- NCT04297917
- Testing
- ChAdOx1-HBV
- Where
- 4 sites in United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Hepatitis C, Chronic
480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)
The purpose of this 12-week study was to assess in subjects with chronic hepatitis C (treatment-naïve, genotype 1) receiving weight-based doses of ribavirin the early virologic response to the 480 ug dose level of Locteron™…
- Trial name
- 480S (NCT00953589)
- Testing
- ribavirin
- Where
- 15 sites in Bulgaria, Israel and 1 more
- Volunteers
- 74 people
- Sponsor
- Biolex Therapeutics, Inc.
Hepatitis B, Chronic
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
- Trial name
- MARCH (NCT04856085)
- Testing
- VIR-2218, VIR-3434, PEG-IFNα
- Where
- 37 sites in United States, Canada and 10 more
- Volunteers
- 244 people
- Sponsor
- Vir Biotechnology, Inc.
Hepatitis B Virus Infection
The Role and Regulatory Mechanism of Germinal Center Immune Response in Hepatitis B Virus Infection
The purpose of this observational study is to investigate the structure and composition of germinal centers in individuals with chronic HBV infection.
- Trial name
- NCT07240350
- Testing
- Tissue resection
- Where
- China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatic Insufficiency
Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment
The primary objectives were: To determine the effects of steady state TPV co-administered with low dose RTV on steady state PegIFN and RBV in HIV negative subjects with mild hepatic impairment (scheme A) To determine the effects…
- Trial name
- NCT02259855
- Testing
- Tipranavir, Ritonavir, Pegylated interferon
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hepatitis C
Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant
The purpose of this study is to determine if the administration of a poorly-absorbable antibiotic (rifaximin) for the first three months after liver transplant will reduce the amount of fibrosis (or scarring of the liver) in…
- Trial name
- Rifaximin (NCT01603108)
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Columbia University
Hepatitis C
Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C
Pegylation of interferon prolongs the medication half-life which has resulted in Pegylated Interferon (PEG-IFN) as the new modality for treatment of chronic hepatitis C.
- Trial name
- NCT00527540
- Testing
- Pegylated Interferon alpha 2a + Ribavirin
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Tehran Hepatitis Center
Hepatitis C, Cognitive Impairment
P300 in Early Cognitive Impairment in Hepatitis C Virus
Approximately 50% of patients with hepatitis C have complaints of fatigue and cognitive deficits even before the development of significant hepatic impairment.
- Trial name
- NCT04389268
- Testing
- Visual Event-Related Potentials
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mansoura University Hospital
Liver Function
The Effect of Chinese Herbal Formula (KSY) on HCV Carrier With Abnormal Liver Function
The aim of the study is to examine whether the Chinese herbal formula (KSY) is effective on HCV Carrier With Abnormal Liver Function.
- Trial name
- NCT01708733
- Testing
- KSY
- Where
- Taiwan
- Volunteers
- 57 people
- Sponsor
- Taipei City Hospital
Hepatitis B
Follow-up of HBsAg Inactive Carriers Study
The definition of HBs antigen (HBsAg) inactive carrier status has evolved during time. We spoke first from HBsAg" healthy carrier ", then from " asymptomatic carrier ", last from HBsAg" inactive carrier ".
- Trial name
- PIBAC (NCT02247752)
- Testing
- inactive carrier
- Where
- 32 sites in France
- Volunteers
- 619 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Chronic Hepatitis B Virus (Hbv)
Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)
Background: People who were born outside of the country are the largest group of adults infected with chronic hepatitis B virus (HBV) in the US. HBV affects the liver.
- Trial name
- NCT05621304
- Where
- 2 sites in United States
- Volunteers
- 274 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C, Chronic
A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients
PPI-383 is an antiviral agent (an inhibitor of the hepatitis C virus NS5B polymerase) that is being developed as a potential treatment for hepatitis C virus infection.
- Trial name
- NCT01928147
- Testing
- PPI-383
- Where
- 6 sites in Mauritius, United Kingdom
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Presidio Pharmaceuticals, Inc.
Hepatitis B, Chronic
A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine
The purpose of this study is to evaluate the efficacy and safety of the investigational medicinal product CVI-HBV-002.
- Trial name
- NCT04289987
- Testing
- CVI-HBV-002
- Where
- 9 sites in South Korea
- Volunteers
- 134 people
- Sponsor
- Aribio Lab Co., Ltd.
Hepatitis B Vaccine
The Immunogenicity and Persistence of Booster Dose With Hepatitis B Vaccine in College Students
The anti-HBs produced after hepatitis B vaccination will decrease over time. College students are vaccinated with hepatitis B vaccine at birth, and their antibodies may have decreased significantly.
- Trial name
- NCT05099757
- Testing
- 20 µg dose hepatitis B vaccine
- Volunteers
- 150 people
- Sponsor
- Shanxi Medical University
Hepatitis C
Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
This is a Phase I/II, multi-site, open-label, single arm study to describe the pharmacokinetics (PK) and safety of glecaprevir/pibrentasvir (GLE/PIB) initiated during pregnancy in women with hepatitis C virus (HCV) infection…
- Trial name
- NCT07040319
- Testing
- Glecaprevir/pibrentasvir
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
The DETECT HCV Linkage to Care Trial
This aim of the DETECT HCV linkage trial compares two linkage to care intervention strategies among (1) newly diagnosed HCV positive patients from the emergency department (ED) and (2) those patients who present to the ED with…
- Trial name
- DETECT HCV (NCT04026867)
- Testing
- Linkage Navigation, Clinician Referral
- Where
- United States
- Volunteers
- 309 people
- Sponsor
- Denver Health and Hospital Authority
Hepatitis C
Acceptance of Hepatitis C Screening by Self-testing in High Risk and General Population
The main purpose of the study is to evaluate the acceptance and viability of self-testing using dried blood spot (DBS) testing assisted by center of origin or referral hospital, as a strategy for screening for hepatitis C virus…
- Trial name
- NCT05146609
- Testing
- Screening HCV. HR-HOSPITAL, Screening HCV. HR-DDP, Screening HCV. GP-HOSPITAL
- Where
- Spain
- Volunteers
- 1,384 people
- Sponsor
- University of La Laguna
Alcoholic Hepatitis
Liver Transplantation in Alcoholic Hepatitis
Patients with alcoholic hepatitis non-responsive to steroids have a poor prognosis. Recently a French-Belgian prospective study has obtained good results (acceptable survival with a low rate of alcohol recidivism).
- Trial name
- SETH-HA (NCT01768715)
- Where
- 17 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Sociedad Española de Trasplante Hepático
Hepatitis C, Chronic
Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis C
Chronic viral hepatitis C is a frequent liver disease. It is associated with variable degree of hepatic fibrosis. To date, liver histology is still regarded as the gold standard to detect, diagnose and quantify liver fibrosis.
- Trial name
- NCT00399815
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.